Drugs / CD19-CAR_Lenti T cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04787263 | Mar 2021 → Mar 2027 expected | acute lymphoblastic leukemia, primary mediastinal large B-cell lymphoma | Bambino Gesù Hospital and Research Institute | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19-CAR_Lenti T cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04787263 ↗ |
| Modality | Cell therapy | “second generation CAR T cells incorporating the 4-1BB costimulatory domain” NCT04787263 ↗ |
| Target | CD19 | “chimeric antigen receptor targeting the B-cell surface antigen CD19” NCT04787263 ↗ |